Brought to you by 
Celgene pays $100mm for exclusive option to buy Acetylon; option expires; Celgene later follows through
20 Aug 2020
Executive Summary
A year-and-a-half after investing $15mm in epigenetics company Acetylon Pharmaceuticals Inc., Celgene Corp. has paid $100mm up front for an exclusive option to buy the firm outright.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com